ChemoCentryx (CCXI) Reports In-Line Q4 EPS

ChemoCentryx (NASDAQ: CCXI) reported Q4 EPS of ($0.28), in-line with the analyst estimate of ($0.28).

For earnings history and earnings-related data on ChemoCentryx (CCXI) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Genco rejects Diana Shipping takeover bid as undervalued
• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform